Application of CD27 as a marker for distinguishing human NK cell subsets
スポンサーリンク
概要
- 論文の詳細を見る
- 2008-04-01
著者
-
Smyth Mark
Cancer Immunology Program Peter Maccallum Cancer Center
-
Smyth Mark
Cancer Immunology Program Trescowthick Laboratories Peter Maccallum Cancer Centre St Andrews Place
-
Hayakawa Yoshihiro
Cancer Immunology Program Trescowthick Laboratories Peter Maccallum Cancer Centre St Andrews Place
-
SILVA Anabel
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Plac
-
ANDREWS Daniel
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Plac
-
BROOKS Andrew
Department of Microbiology and Immunology, University of Melbourne
-
Silva Anabel
Cancer Immunology Program Trescowthick Laboratories Peter Maccallum Cancer Centre St Andrews Place
-
Brooks Andrew
Department Of Microbiology And Immunology University Of Melbourne
-
Andrews Daniel
Cancer Immunology Program Trescowthick Laboratories Peter Maccallum Cancer Centre St Andrews Place
関連論文
- Combination antibody-based cancer immunotherapy
- TRAIL and its receptors as targets for cancer therapy
- NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
- No requirement for TRAIL in intrathymic negative selection
- Application of CD27 as a marker for distinguishing human NK cell subsets
- Persistent expression of CD94/NKG2 receptors by virus-specific CD8 T cells is initiated by TCR-mediated signals
- Prime-boost immunization generates a high frequency, high-avidity CD8^+ cytotoxic T lymphocyte population